SAB Biotherapeutics announced its new name, SAB BIO, and visual identity to more closely align with its mission to treat and prevent immune and autoimmune disorders with the use of its unique immunotherapy platform. This rebrand includes a new name, logo mark and website updates to reflect the company’s strategic evolution. “Our business has transformed significantly in the past year, with our singular focus on developing therapies that have the potential to slow disease progression in patients with new or recent onset stage 3 type 1 diabetes,” said Samuel J. Reich, Chairman and CEO of SAB BIO. “Refreshing our corporate brand to reflect our vision for a new type 1 diabetes therapy was an important step to align our identity with our plan for clinical development and presence within the type 1 diabetes community.” The rebrand is announced in advance of SAB’s poster presentation at the American Diabetes Association 84th Scientific Sessions on June 21-24 in Orlando, Florida.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAb Biotherapeutics Rebrands as SAB BIO
- SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
- SAB Biotherapeutics initiated with Buy on risk/reward at Brookline
- SAB Biotherapeutics initiated with a Buy at Brookline
- SAB Biotherapeutics Appoints Mr. Conley, Details Public Disclosure